Specialty Tiers Ensure Part D Plans Cover High-Cost Biologics, Blum Says

By Cathy Kelly / Email the Author / The RPM Report January 2012, Vol. 8, No. 2
CMS Beat / Word Count: 848 / Article # 2012500012

Executive Summary

CMS Medicare director Jonathan Blum acknowledges there is a “robust debate” within CMS regarding specialty tiers in Part D but says he believes permitting plans to charge beneficiaries higher cost-sharing for expensive biologics preserves access to such drugs.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 848-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Specialty Tiers Ensure Part D Plans Cover High-Cost Biologics, Blum Says

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to The RPM Report will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Specialty Tiers Ensure Part D Plans Cover High-Cost Biologics, Blum Says

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 5

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article